NCT04387227
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 29 versions: 26 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 20, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 13 words
- Secondary endpoints revised (3)
- Primary endpoints revised (2)
- Site details revised
- Minor Trial status: Active, Not Recruiting to Completedv28
- Minor Primary completion date changed from estimate of Jun 30, 2025 to Sep 12, 2025
- Study completion date: Dec 31, 2025 to Jun 1, 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Secondary endpoints: 4 to 3
- Site details revised
- Notable Primary completion date: Dec 31, 2024 to Jun 30, 2025v25
Show 20 earlier versionsHide 20 earlier versions
- Notable Primary completion date: Apr 3, 2024 to Dec 31, 2024
- Study completion date: Apr 3, 2025 to Dec 31, 2025
- Notable Eligibility criteria expanded, about 12 words
- Interventions: Carboplatin (Drug), Pembrolizumab (Biological) to Biospecimen Collection (Procedure), Carboplatin (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…
- Study description expanded, about 22 words
- Notable Primary completion date: Apr 3, 2023 to Apr 3, 2024
- Study completion date: Apr 3, 2024 to Apr 3, 2025
- Notable Eligibility criteria shortened, about 10 wordsv19
- Notable Eligibility criteria expanded, about 33 wordsv18
- Minor Start date changed from estimate of Jun 26, 2021 to Mar 18, 2021v17
- Notable Start date: May 26, 2021 to Jun 26, 2021v16
- Notable Start date: Apr 24, 2021 to May 26, 2021v15
- Notable Start date: Mar 24, 2021 to Apr 24, 2021v14
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Mar 11, 2021 to Mar 24, 2021
- Site details revised
- Notable Eligibility criteria expanded, about 3 words
- Start date: Feb 11, 2021 to Mar 11, 2021
- Study description revised
- Notable Start date: Jan 9, 2021 to Feb 11, 2021v10
- Notable Start date: Dec 9, 2020 to Jan 9, 2021v9
- Notable Start date: Nov 5, 2020 to Dec 9, 2020v8
- Notable Start date: Oct 3, 2020 to Nov 5, 2020v7
- Notable Start date: Sep 3, 2020 to Oct 3, 2020v6
- Notable Start date: Aug 1, 2020 to Sep 3, 2020v5
- Notable Start date: Jul 1, 2020 to Aug 1, 2020v4
- Notable Start date: Jun 1, 2020 to Jul 1, 2020v3
- Minor Site contact updatedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Rate of Radiographic Recurrence
Timeframe: At 6 months
Progression Free Survival
Timeframe: Up to 2 years
Secondary (3)
Programmed Cell Death Ligand 1 (PD-L1) Expression
Changes in T Cell Activation
Overall Survival
Arms and interventions
Treatment (carboplatin, pembrolizumab)Experimental
Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.
Drugs: Carboplatin
Biologicals: Pembrolizumab
Procedures: Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States